Strategies to overcome CAR-T cell resistance in clinical work: A single-institute experience

Front Immunol. 2022 Aug 10:13:929221. doi: 10.3389/fimmu.2022.929221. eCollection 2022.

Abstract

The emergence of chimeric antigen receptor (CAR) T cell therapy has shifted the paradigm of malignant tumor treatment, especially the advent of CD19-directed CAR-T cell therapy for the treatment of relapsed/refractory (R/R) B-cell malignancies. Although CAR-T cell therapy has promising effects, some patients are resistant to this treatment, leaving them with limited options. Therefore, strategies to overcome resistance to CAR-T cell therapy are needed. We retrospectively studied three R/R diffuse large B-cell lymphoma patients who were resistant to CAR-T cell therapy and whose disease was controlled after receiving pembrolizumab, 21D4 CAR-T cells, or ibrutinib and venetoclax. Some promising prevention and treatment strategies to overcome treatment resistance are also discussed.

Keywords: CAR-T cell therapy; PD-1 inhibitor; ibrutinib; resistance; venetoclax.

MeSH terms

  • Humans
  • Neoplasm Recurrence, Local
  • Receptors, Antigen, T-Cell
  • Receptors, Chimeric Antigen*
  • Retrospective Studies
  • T-Lymphocytes*

Substances

  • Receptors, Antigen, T-Cell
  • Receptors, Chimeric Antigen